Search

Genmab A-S

Fechado

2,475 1.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2434

Máximo

2471

Indicadores-chave

By Trading Economics

Rendimento

243M

295M

Vendas

259M

1.2B

P/E

Médio do Setor

29.317

47.946

EPS

34.85

Margem de lucro

25.541

Funcionários

3,119

EBITDA

216M

431M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-1.49% downside

Dividendos

By Acuity

Próximos Ganhos

5 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

35B

148B

Abertura anterior

2473.44

Fecho anterior

2475

Genmab A-S Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de out. de 2026, 23:51 UTC

Canada's Housing Starts Data Set for Release Amidst Weak Employment Figures, Forecasting 230K Units and Cautious Market Sentiment.

10 de out. de 2026, 23:41 UTC

Market Awaits NY Empire State Manufacturing Index Release Amid Cautious Optimism and Broader Economic Concerns on October 15, 2026.

10 de out. de 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index for October 2026 set to release with optimistic growth forecast amid inflation concerns and upcoming earnings reports.

10 de out. de 2026, 23:41 UTC

Core Producer Prices Expected to Rise 0.3% in September, Amid Cautious Market Sentiment and Inflation Concerns Ahead of Key Economic Reports

10 de out. de 2026, 23:41 UTC

US Producer Price Index Expected to Rise 0.5% Amidst Deteriorating Consumer Confidence and Inflation Concerns Ahead of October Release

10 de out. de 2026, 23:31 UTC

Australia's upcoming employment data release on October 15 is crucial, following a significant decline in full-time jobs and amid cautious economic sentiment influenced by global market fluctuations.

10 de out. de 2026, 23:31 UTC

Australia's Unemployment Rate Expected to Rise to 4.6% in September, Sparking Concerns Over Labor Market Stability Amid Global Economic Volatility

10 de out. de 2026, 23:31 UTC

Australia's Employment Change Report on October 15 Expected to Show Job Growth Amid Global Labor Market Concerns.

10 de out. de 2026, 23:21 UTC

US CPI Release on October 14 Sparks Caution Among Investors Amid Declining Consumer Sentiment and Inflation Concerns

10 de out. de 2026, 23:21 UTC

U.S. CPI data release on October 14 expected to show inflation rise to 3.6%, amid declining consumer confidence and fears of Federal Reserve tightening ahead of midterm elections.

10 de out. de 2026, 23:21 UTC

Core Inflation Rate Release on October 14, 2026, Expected to Rise by 0.2%, Influencing Federal Reserve Interest Rate Decisions Amidst Cautious Market Sentiment and Consumer Concerns Over Rising Costs.

10 de out. de 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.6% in September Amid Consumer Confidence Decline and Geopolitical Tensions, Influencing Federal Reserve Policy Discussions

10 de out. de 2026, 23:21 UTC

Market Anticipates CPI Release Amid Rising Inflation Concerns and Mixed Investor Sentiment

10 de out. de 2026, 23:21 UTC

Core Inflation Rate for September 2026 Expected to Rise Slightly to 2.5%, Heightening Market Caution Amidst Rising Consumer Sentiment and Geopolitical Tensions.

10 de out. de 2026, 23:11 UTC

Brazil's Retail Sales Data Release on October 15 Expected to Reveal Consumer Spending Trends Amid Cautious Market Sentiment.

10 de out. de 2026, 23:01 UTC

Macro News

The Dow Jones Index (US) is trading roughly flat in after-market hours amid concerns over semiconductor stocks and heightened geopolitical tensions.

10 de out. de 2026, 22:51 UTC

Japan's Machinery Orders MoM data for August, set to release on October 14, is expected to show a modest 2.5% growth amid mixed manufacturing sentiment and concerns over softening demand.

10 de out. de 2026, 22:51 UTC

Australia's NAB Business Confidence report set for October 13 reveals cautious market sentiment amid declining confidence and rising costs, raising concerns over economic stability.

10 de out. de 2026, 22:51 UTC

RBA Meeting Minutes on October 13, 2026, Expected to Influence Interest Rate Decisions Amid Inflation Concerns and Global Economic Factors.

10 de out. de 2026, 22:51 UTC

The Nikkei 225 Index is roughly flat in after-market trading, holding steady since Friday's close amid positive sentiment ahead of upcoming corporate earnings reports.

10 de out. de 2026, 22:41 UTC

Singapore's Q3 2026 GDP Growth Rate Release on October 14 Sparks Cautious Optimism Amid Economic Recovery Signs and Mixed Asian Market Sentiments.

10 de out. de 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit 7.49% Amid Rising Treasury Yields and Inflation Concerns, Forecasting Continued Upward Pressure on Housing Market Demand

10 de out. de 2026, 22:31 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Rising Inflation on October 13, 2026.

10 de out. de 2026, 22:21 UTC

South Korea's Unemployment Rate Release on October 15 Expected to Reflect Labor Market Resilience Amid Global Economic Pressures.

10 de out. de 2026, 22:01 UTC

Spain's Consumer Confidence Index set for October 13 release amid cautious sentiment due to inflation and geopolitical tensions.

10 de out. de 2026, 21:31 UTC

Italy's Balance of Trade data set for October 16, with a forecasted €7.5 billion surplus amid cautious sentiment following disappointing industrial production figures.

10 de out. de 2026, 21:31 UTC

UK Retail Sales Monitor YoY for September 2026 Expected to Show Modest 0.7% Increase Amid Cautious Consumer Sentiment and Inflation Concerns

10 de out. de 2026, 20:41 UTC

India's Inflation Rate YoY Release on October 12, 2026, Expected to Reflect Ongoing Energy Price Pressures Amid Optimistic Market Sentiment.

10 de out. de 2026, 20:31 UTC

API Crude Oil Stock Change Report on October 14, 2026, to Reflect Inventory Fluctuations Amid Geopolitical Tensions and Market Caution Ahead of Key Inflation Data.

10 de out. de 2026, 20:31 UTC

Fed Governor Barkin's Upcoming Speech Sparks Cautious Market Sentiment Amid Inflation Concerns and Key Economic Data Releases.

Comparação entre Pares

Variação de preço

Genmab A-S Previsão

Preço-alvo

By TipRanks

-1.49% parte inferior

Previsão para 12 meses

Média 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Genmab A-S - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

7 ratings

3

Comprar

2

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.